Review Article: Switching Patients with Chronic Hepatitis B to Tenofovir Alafenamide-a Review of Current Data

Overview

Journal Aliment Pharmacol Ther

Specialties Gastroenterology
Pharmacology

Date 2022 Feb 18

PMID 35178711

Authors

Young-Suk Lim

Wai-Kay Seto

Masayuki Kurosaki

Scott Fung

Jia-Horng Kao

Jinlin Hou

Stuart C Gordon

John F Flaherty

Leland J Yee

Yang Zhao

Kosh Agarwal

Pietro Lampertico

Affiliations

Soon will be listed here.

Abstract

Background: The nucleos(t)ide analogues (NAs) entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are preferred treatment options for patients with chronic hepatitis B infection (CHB). However, resistance to ETV has been reported, especially with prior exposure to other NAs, and long-term TDF treatment has been associated with decline in renal function and loss of bone mineral density in some patients. Consequently, TAF may be preferable to ETV, TDF or other NAs in specific circumstances such as in patients with risk of bone or renal complications, elderly patients or those with previous NA experience.

Aim: To provide a summary of the available efficacy and safety data following switch to TAF from other NAs in patients with CHB in clinical studies and real-world settings.

Methods: Literature searches were performed on PubMed and abstracts from three major international liver congresses between 2019 and 2021. Studies that included efficacy and/or safety data for patients with CHB switching from any NA to TAF were selected.

Results: Thirty-six papers and abstracts were included in this narrative review. Switching from TDF to TAF maintained or improved virological and biochemical responses with improved bone and renal safety. Switching from ETV or other NAs to TAF maintained or improved virological and biochemical responses and varying results for bone and renal safety.

Conclusions: Switching to TAF appears to maintain or improve virological, biochemical and bone- and renal-related safety outcomes. These data support the concept of switching to TAF in some patients with CHB based on their individual circumstances.

Citing Articles

Lower incidence of hepatocellular carcinoma with tenofovir alafenamide in chronic hepatitis B: Evidence from a large-scale cohort.

Yoo H, Kim J, Yoo J, Lee H, Kim S, Kim Y JHEP Rep. 2025; 7(2):101268.

PMID: 39867683 PMC: 11762169. DOI: 10.1016/j.jhepr.2024.101268.

Prospective Analysis of Safety and Efficacy of Tenofovir Alafenamide Fumarate (TAF) in European Real-World Patients with Chronic Hepatitis B: A Single-Centre Real-Word Cohort Study.

Fulop B, Fischer J, Hahn M, Bohlig A, Matz-Soja M, Berg T Pathogens. 2024; 13(9).

PMID: 39339010 PMC: 11434708. DOI: 10.3390/pathogens13090820.

Improvement of hepatic fibrosis after tenofovir disoproxil fumarate switching to tenofovir alafenamide for three years.

Huynh T, Bui D, Zhou T, Hu K World J Hepatol. 2024; 16(7):1009-1017.

PMID: 39086529 PMC: 11287611. DOI: 10.4254/wjh.v16.i7.1009.

Five-year Treatment with Tenofovir Alafenamide Achieves High Rates of Viral Suppression, Alanine Aminotransferase Normalization, and Favorable Bone and Renal Safety in Chinese Chronic Hepatitis B Patients.

Hou J, Ning Q, Duan Z, Chen Y, Xie Q, Zhang L J Clin Transl Hepatol. 2024; 12(5):469-480.

PMID: 38779514 PMC: 11106352. DOI: 10.14218/JCTH.2023.00417.

Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B.

Liu R, Qiao J, Zhang L, Dou Z Medicine (Baltimore). 2024; 103(20):e37953.

PMID: 38758884 PMC: 11098221. DOI: 10.1097/MD.0000000000037953.

References

Lee W, He G, Eisenberg E, Cihlar T, Swaminathan S, Mulato A . Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005; 49(5):1898-906. PMC: 1087627. DOI: 10.1128/AAC.49.5.1898-1906.2005. View

Uchida Y, Nakao M, Tsuji S, Uemura H, Kouyama J, Naiki K . Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate. J Med Virol. 2019; 92(3):329-338. DOI: 10.1002/jmv.25644. View

Jung W, Jang J, Park W, Jeong S, Lee H, Park S . Effect of tenofovir on renal function in patients with chronic hepatitis B. Medicine (Baltimore). 2018; 97(7):e9756. PMC: 5839852. DOI: 10.1097/MD.0000000000009756. View

. [The guidelines of prevention and treatment for chronic hepatitis B (2019 version)]. Zhonghua Gan Zang Bing Za Zhi. 2020; 27(12):938-961. DOI: 10.3760/cma.j.issn.1007-3418.2019.12.007. View

Fong T, Lee B, Tien A, Chang M, Lim C, Ahn A . Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. J Viral Hepat. 2018; 26(5):561-567. DOI: 10.1111/jvh.13053. View

Ford N, Scourse R, Lemoine M, Hutin Y, Bulterys M, Shubber Z . Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis. Hepatol Commun. 2018; 2(10):1160-1167. PMC: 6167073. DOI: 10.1002/hep4.1247. View

Su T, Hu T, Chen C, Huang Y, Chuang W, Lin C . Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016; 36(12):1755-1764. DOI: 10.1111/liv.13253. View

Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2015; 10(1):1-98. PMC: 4722087. DOI: 10.1007/s12072-015-9675-4. View

Notsumata K, Nomura Y, Tanaka A, Ueda T, Sanada T, Watanabe H . Early changes in tubular dysfunction markers and phosphorus metabolism regulators as a result of switching from entecavir to tenofovir alafenamide fumarate nucleoside analog therapy for chronic hepatitis B patients. Hepatol Res. 2019; 50(3):402-404. DOI: 10.1111/hepr.13451. View

10.

Li Z, Li L, Niu X, Chen S, Fu Y, Wang C . Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia. Liver Int. 2021; 41(6):1254-1264. DOI: 10.1111/liv.14786. View

11.

Zeng Q, Yu Z, Ji F, Li G, Zhang G, Xu J . Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study. Clin Infect Dis. 2021; 73(9):e3324-e3332. DOI: 10.1093/cid/ciaa1939. View

12.

Lampertico P, Buti M, Fung S, Ahn S, Chuang W, Tak W . Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol. 2020; 5(5):441-453. DOI: 10.1016/S2468-1253(19)30421-2. View

13.

Murakami E, Wang T, Park Y, Hao J, Lepist E, Babusis D . Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob Agents Chemother. 2015; 59(6):3563-9. PMC: 4432166. DOI: 10.1128/AAC.00128-15. View

14.

Nguyen M, Atsukawa M, Ishikawa T, Yasuda S, Yokohama K, Trinh H . Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir. Am J Gastroenterol. 2021; 116(6):1264-1273. DOI: 10.14309/ajg.0000000000001157. View

15.

Byun K, Choi J, Kim J, Lee Y, Lee H, Kim Y . Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate. Clin Gastroenterol Hepatol. 2021; 20(2):427-437.e5. DOI: 10.1016/j.cgh.2021.04.045. View

16.

Tien C, Xu J, Chan L, Chang M, Lim C, Lee S . Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling. Dig Dis Sci. 2014; 60(2):566-72. DOI: 10.1007/s10620-014-3363-4. View

17.

Lim Y, Seto W, Kurosaki M, Fung S, Kao J, Hou J . Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. Aliment Pharmacol Ther. 2022; 55(8):921-943. PMC: 9304567. DOI: 10.1111/apt.16788. View

18.

Bernstein D, Trinh H, Schiff E, Smith C, Mospan A, Zink R . Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV. Dig Dis Sci. 2021; 67(6):2637-2645. DOI: 10.1007/s10620-021-07033-y. View

19.

Millan J, Pinto X, Munoz A, Zuniga M, Rubies-Prat J, Pallardo L . Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009; 5:757-65. PMC: 2747394. View

20.

Wong G, Wong V, Yuen B, Tse Y, Luk H, Yip T . An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017. Hepatology. 2019; 71(2):444-455. DOI: 10.1002/hep.30833. View